STOCK TITAN
  1. Home
  2. News
  3. AWH

Aspira Women's Health Inc. - $AWH STOCK NEWS

Welcome to our dedicated page for Aspira Women's Health news (Ticker: $AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aspira Women's Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aspira Women's Health's position in the market.

News
Aspira Women’s Health Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) reported a 9% increase in product revenue to $2.2 million for the quarter and a 19% increase to $7.0 million year to date. OvaSuite sales volume increased 5% to 5,783 units for the quarter and 16% to 18,331 units year to date. The company also highlighted significant achievements in the development of new products and the establishment of a Clinical Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
earnings
-
News
Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) announces that CMS has proposed to crosswalk the reimbursement rate for OvaWatch to Ova1 at $897 per test, pending finalization in January 2024. This move supports Aspira's mission to gain broad reimbursement coverage for their non-invasive ovarian cancer identification tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
none
-
News
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023
Rhea-AI Summary
Aspira Women’s Health Inc. will report its financial results for the three months ended September 30, 2023 on November 13, 2023. The company will host a conference call with investors at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Participants can join the call using the provided toll-free and international numbers or access the event instantly through the Call me™ link. A replay of the webcast will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
earnings
News
Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research
Rhea-AI Summary
Aspira Women’s Health announces promising findings on an in-development miRNA-based ovarian cancer test. The study shows that miRNA has the potential to improve the diagnostic accuracy of non-invasive diagnostic tests for early-stage ovarian cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
none
-
News
Aspira Women’s Health Establishes a New Clinical Advisory Board
Rhea-AI Summary
Aspira Women’s Health Inc. has established a Clinical Advisory Board to develop and distribute diagnostic tools for gynecologic diseases. The board consists of preeminent physicians with deep clinical expertise in gynecologic health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
management
-
News
Aspira Women’s Health to Present at the BioVenture Nexus Conference
Rhea-AI Summary
Aspira Women’s Health Inc. will present a brief corporate overview at the BioVenture Nexus Conference on October 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences
News
Aspira Women’s Health Regains Nasdaq Compliance
Rhea-AI Summary
Aspira Women’s Health regains compliance with Nasdaq listing requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.34%
Tags
none
-
News
Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer
Rhea-AI Summary
Aspira Women's Health appoints Jody Berry as new Chief Scientific Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none
-
News
Aspira Women’s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford
Rhea-AI Summary
Aspira Women’s Health Inc. has announced a material transfer agreement with The University of Oxford to procure serum samples for the development and validation of its endometriosis blood test. The company expects to launch the test, called EndoCheck, by the end of 2023. This test aims to provide a non-invasive method for diagnosing endometriosis, a condition that affects over six million women in the U.S. and often leads to years of pain before diagnosis. Aspira believes that the availability of a simple blood test will support the development of new therapeutic solutions and help patients access treatments sooner.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.57%
Tags
none
News
Aspira Women’s Health to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Aspira Women’s Health Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
Stock AWH logo
Aspira Women's Health Inc.

Nasdaq:AWH

AWH Rankings

#4991 Ranked by Market Cap
#3410 Ranked by Stock Gains
N/A Ranked by Dividends

AWH Stock Data

32.84M
9.36M
38.84%
9.09%
1.09%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
AUSTIN

About AWH

vermillion, inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. the company’s initial in vitro diagnostic test, ova1®, was the first fda-cleared, protein-based in vitro diagnostic multivariate index assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. in march 2016 vermillion received fda clearance for overa™, a second generation ova1 test with significantly improved specificity and ease of use.